We are live on
!
Find out more
HC
Henshaw Capital Portfolio holdings
AUM
$3.07B
Turnover
11.76%
1-Year Est. Return
40.85%
This Fund
S&P 500
This Quarter
Est. Return
-13.93%
1 Year Est. Return
+40.85%
3 Year Est. Return
+128.2%
5 Year Est. Return
+170.36%
10 Year Est. Return
+567.65%
AUM
$1.44B
AUM Growth
-$266M
(-16%)
Cap. Flow
-$4.59M
Cap. Flow
% of AUM
-0.32%
Top 10 Holdings %
Top 10 Hldgs %
33.34%
Holding
325
New
10
Increased
75
Reduced
47
Closed
24
Avg Time Held
3.1
years
Top 10 Avg Time Held
3.5
years
Top 20 Avg Time Held
3.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burlington
BURL
|
+$598K |
| 2 |
Teleflex
TFX
|
+$547K |
| 3 |
GoDaddy
GDDY
|
+$471K |
| 4 |
Bristol-Myers Squibb
BMY
|
+$452K |
| 5 |
Xometry
XMTR
|
+$416K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$999K |
| 2 |
Citigroup
C
|
+$675K |
| 3 |
W.R. Berkley
WRB
|
+$655K |
| 4 |
Carlisle Companies
CSL
|
+$506K |
| 5 |
WillScot Mobile Mini Holdings
WSC
|
+$502K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.14% |
| 2 | Industrials | 16.41% |
| 3 | Healthcare | 12.77% |
| 4 | Financials | 11.85% |
| 5 | Communication Services | 10.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Prosperity Bancshares
PB
$8.15B
| $1.06M | 0.07% |
15,506
| – | – |
2018 Q3
15 quarters
|
|
102
Graco
GGG
$13.3B
| $1.05M | 0.07% |
17,738
+59
| +0.3% | +$3.71K |
2016 Q1
25 quarters
|
|
103
Pool Corp
POOL
$6.27B
| $1.04M | 0.07% |
2,954
+269
| +10% | +$107K |
2018 Q3
15 quarters
|
|
104
Manhattan Associates
MANH
$13B
| $1M | 0.07% |
8,764
| – | – |
2016 Q1
25 quarters
|
|
105
Northrop Grumman
NOC
$73.9B
| $981K | 0.07% |
2,049
+7
| +0.3% | +$3.21K |
2017 Q3
19 quarters
|
|
106
Johnson & Johnson
JNJ
$616B
| $960K | 0.07% |
5,410
-1,660
| -23% | -$296K |
2017 Q3
19 quarters
|
|
107
Cigna
CI
$79.9B
| $955K | 0.07% |
3,623
-465
| -11% | -$120K |
2017 Q3
19 quarters
|
|
108
Diageo
DEO
$52.9B
| $917K | 0.06% |
5,269
-1,077
| -17% | -$205K |
2019 Q4
10 quarters
|
|
109
Jack Henry & Associates
JKHY
$10.7B
| $914K | 0.06% |
5,078
+14
| +0.3% | +$2.62K |
2016 Q1
25 quarters
|
|
|
110
Burlington
BURL
$16.5B
| $905K | 0.06% |
6,643
+3,304
| +99% | +$598K |
2020 Q1
9 quarters
|
|
111
Accenture
ACN
$141B
| $902K | 0.06% |
3,250
+9
| +0.3% | +$2.7K |
2017 Q1
21 quarters
|
|
112
Trimble
TRMB
$13.9B
| $857K | 0.06% |
14,713
+5,446
| +59% | +$358K |
2016 Q4
22 quarters
|
|
113
Factset
FDS
$10.7B
| $841K | 0.06% |
2,186
+5
| +0.2% | +$1.96K |
2016 Q1
25 quarters
|
|
114
Sony
SONY
$145B
| $807K | 0.06% |
49,350
-4,810
| -9% | -$85.2K |
2019 Q2
12 quarters
|
|
115
AstraZeneca
AZN
$257B
| $799K | 0.06% |
6,050
-293
| -5% | -$38.4K |
2019 Q1
13 quarters
|
|
116
Southern Company
SO
$105B
| $780K | 0.05% |
10,940
| – | – |
2019 Q3
11 quarters
|
|
117
Shell
SHEL
$303B
| $777K | 0.05% |
14,855
| – | – |
2022 Q1
1 quarter
|
|
118
Duke Energy
DUK
$94.7B
| $760K | 0.05% |
7,085
-1,072
| -13% | -$118K |
2017 Q3
19 quarters
|
|
119
Texas Instruments
TXN
$252B
| $757K | 0.05% |
4,926
+32
| +0.7% | +$5.38K |
2017 Q3
19 quarters
|
|
120
ConocoPhillips
COP
$176B
| $737K | 0.05% |
8,203
-1,942
| -19% | -$200K |
2020 Q4
6 quarters
|
|
121
Novo Nordisk
NVO
$171B
| $731K | 0.05% |
13,114
-210
| -2% | -$11.7K |
2019 Q4
10 quarters
|
|
122
Deckers Outdoor
DECK
$11.7B
| $726K | 0.05% |
17,052
| – | – |
2020 Q4
6 quarters
|
|
123
Morgan Stanley
MS
$284B
| $702K | 0.05% |
9,224
| – | – |
2021 Q1
5 quarters
|
|
124
Woodward
WWD
$19.4B
| $689K | 0.05% |
7,451
| – | – |
2020 Q4
6 quarters
|
|
125
Henry Schein
HSIC
$9.63B
| $664K | 0.05% |
8,652
| – | – |
2016 Q1
25 quarters
|
|
Similar funds
Henshaw Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Henshaw Capital held 325 positions worth $1.44B, down 16% from $1.71B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Henshaw Capital's Q2 2022 filing shows 10 new, 75 increased, 47 reduced and 24 closed positions. Its largest new stake was Bristol-Myers Squibb: 5,930 shares worth $457K. The largest sale was Dentsply Sirona, an estimated $999K.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 26% a quarter earlier, followed by Industrials and Healthcare.
- Henshaw Capital's largest Q2 2022 buy was Bristol-Myers Squibb: 5,930 shares worth $457K.
- Henshaw Capital added most to Burlington in Q2 2022, an estimated $598K increase.
- Henshaw Capital's biggest Q2 2022 reduction was Citigroup, cutting an estimated $675K.
- Henshaw Capital fully exited Dentsply Sirona in Q2 2022, selling an estimated $999K.
- Henshaw Capital's ten largest holdings make up 33% of its $1.44B portfolio in Q2 2022.
- Henshaw Capital opened 10 new positions and closed 24 in Q2 2022.
- Henshaw Capital's portfolio value fell 16% quarter-over-quarter to $1.44B.
Based on Henshaw Capital's 13F filing for Q2 2022, filed 28 May 2026.